$164 Million is the total value of MPM BioImpact LLC's 10 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ARGX | Exit | argenx SE | $0 | – | -71,700 | -100.0% | -4.08% | – |
DCPH | Exit | Deciphera Pharmaceuticals, Inc. | $0 | – | -215,570 | -100.0% | -4.76% | – |
ARQL | Exit | ArQule, Inc. | $0 | – | -1,094,210 | -100.0% | -7.74% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-13
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Repare Therapeutics, Inc. | 17 | Q2 2024 | 19.7% |
iTeos Therapeutics, Inc. | 16 | Q2 2024 | 15.7% |
Harpoon Therapeutics, Inc. | 15 | Q2 2023 | 27.6% |
Cullinan Therapeutics, Inc. | 14 | Q2 2024 | 41.4% |
TCR2 Therapeutics, Inc. | 14 | Q1 2023 | 18.0% |
G1 Therapeutics, Inc. | 13 | Q4 2022 | 13.3% |
Intellia Therapeutics, Inc. | 13 | Q2 2024 | 5.5% |
Werewolf Therapeutics, Inc. | 13 | Q2 2024 | 6.8% |
Y Mabs Therapeutics, Inc. | 12 | Q3 2022 | 5.4% |
Crinetics Pharmaceuticals Inc. | 12 | Q2 2024 | 4.0% |
View MPM BioImpact LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-08-21 |
13F-HR | 2024-08-14 |
13F-HR | 2024-05-15 |
13F-HR | 2024-02-13 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
SC 13D/A | 2023-08-01 |
SC 13D | 2023-06-12 |
4 | 2023-06-05 |
13F-HR | 2023-05-12 |
View MPM BioImpact LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.